Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From KEDI Global Longevity Bio Index (KGLB)
8/17/2026, 12:00:00 AM
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
Korean Translation
2026년 8월 17일 미국 FDA의 이베르도마이드 신약 허가 신청에 대한 PDUFA 목표 심사 완료일 지정. 행정적 일정 확정으로 주가 영향이 적을 것으로 예상되어 중요도를 'Low'로 평가함.
Related Recent Events
Exelixis Inc (EXEL) · Other
U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.
12/3/2026, 12:00:00 AM
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.
7/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol-Myers Squibb Q2 2026 earnings release on 2026-07-30 scheduled; importance is Low as the announcement of an earnings date typically has a <5% price impact.
7/30/2026, 12:00:00 AM